ViroGates Releases Third Quarter 2019 Results
Company announcement no. 13-2019 Birkerød, 28 October 2019 ViroGates A/S (Nasdaq First North Growth Market Denmark: VIRO), who delivers blood test systems for emergency departments in hospitals, to...
- Supported exchanges /
- CO /
- VIRO.CO
ViroGates A/S (VIRO CO) stock market data APIs
kr16
0.6(3.9%)
as of November 22, 2024
Price chart is built with Anychart
ViroGates A/S, an in vitro diagnostics company, develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital emergency services to support the clinical decision on hospitalization or discharge of acute patients and to identify high-risk sepsis patients at an early stage, as well as used for the prognosis of lifestyle-related diseases, such as cardiovascular disease, type 2 diabetes, and cancer; and for the assessment of longevity and biological age in a non-hospital setting. The company' products icludes suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the soluble urokinase plasminogen activator receptor (suPAR) level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic ELISA that provides fully quantitative results; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging that will allow clinicians and nurses to obtain a fast patient prognosis for patient disease severity, progression and outcome; and suPARnostic POC+, a point-of-care finger prick test that detects the level of suPAR in the blood. The company was founded in 2000 and is headquartered in Birkerød, Denmark.
ViroGates A/S Financial Data Overview
| 15.71 | |
| 16 | |
| - | |
| 17.07 | |
| 12.39 | |
| 4.98-31 | |
| 119 M | |
| 7 734 K | |
| 7 248 K | |
| -0.8788 | |
| 0.78 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'VIRO',
Type:
'Common Stock',
Name:
'ViroGates A/S',
Exchange:
'CO',
CurrencyCode:
'DKK',
CurrencyName:
'Danish krone',
CurrencySymbol:
'kr',
CountryName:
'Denmark',
CountryISO:
'DK',
OpenFigi:
NULL,
ISIN:
'DK0061030574',
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'December',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Medical Devices',
}
ViroGates A/S Fundamental Data is available in our Financial Data APIs
- Net Revenue 7 248 K
- EBITDA -13 101 000
- Earnings Per Share -2.98
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get ViroGates A/S Earnings via APIs
- Latest Release 2023-05-04
- EPS/Forecast NaN
Get ViroGates A/S End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get ViroGates A/S latest news via APIs
ViroGates announces clinical implementation of suPARnostic® TurbiLatex at University Hospital of Montpellier France
Company announcement no. 12-2019 Birkerød, 3 September 2019 ViroGates A/S (Nasdaq First North Growth Market Denmark: VIRO), who delivers blood test systems, primarily for acute care departments in ...
- COPENHAGEN STOCK EXCHANGE:VIRO
- VIROGATES A/S
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
